Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398149 | 1.00 | MEN1 (0.49) | MEN1TSHRKMT2ASIGMAR1GAA | |
| SCHEMBL3312293 | 1.00 | MEN1 (0.49) | MEN1TSHRKMT2ASIGMAR1GAA | |
| SCHEMBL15645984 | 0.77 | SIGMAR1 (0.48) | SIGMAR1GAANR3C1CYP2D6GRIN1 | |
| SCHEMBL3315042 | 0.77 | NR3C1 (0.49) | MEN1KMT2ASIGMAR1GAANR3C1 | |
| SCHEMBL7270268 | 0.76 | SIGMAR1 (0.61) | MEN1TSHRKMT2ASIGMAR1GAA | |
| SCHEMBL4501240 | 0.73 | SIGMAR1 (0.52) | MEN1TSHRKMT2ASIGMAR1GAA | |
| SCHEMBL4501237 | 0.73 | SIGMAR1 (0.52) | MEN1TSHRKMT2ASIGMAR1GAA | |
| SCHEMBL10365169 | 0.73 | SIGMAR1 (0.52) | MEN1TSHRKMT2ASIGMAR1GAA | |
| SCHEMBL5265862 | 0.72 | CYP2D6 (0.44) | MEN1TSHRKMT2ASIGMAR1GAA | |
| SCHEMBL5265856 | 0.72 | CYP2D6 (0.44) | MEN1TSHRKMT2ASIGMAR1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105661-A1 | CONDENSED PYRIDINE COMPOUND | JAK3, IRAK3, JAK1 | MEN1 3755/4885TSHR 4191/4885KMT2A 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.